Close mobile menu×
Close mobile menu

Mishaela R. Rubin, MD

Board Certifications: 
Endocrinology
Accepting New Patients
Profile Headshot

Appointments

Phone Appointments

New and Existing Patients: 
(212) 305-2663

myColumbiaDoctors

For existing patients, login to make an appointment, view documentation or contact your care provider.

Credentials & Experience

Board Certifications

  • Endocrinology

Clinical Expertise

  • Hypothyroidism
  • Bone Disease
  • Metabolic Bone Disease

Education & Training

  • Columbia University College of Physicians and Surgeons
  • Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
  • Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center

Honors & Awards

  • Phi Beta Kappa, Barnard College, 1991
  • Endocrine Fellows Foundation Award
  • Mentored Patient-Oriented Research Career Development Award (K23, NIH), 2004-2009
  • Patient-Oriented Research Track Scholarship (K30, NIH), 2004-2006
  • Young Investigator Award, American Society of Bone and Mineral Research, 2006

About Mishaela Rubin

Dr. Mishaela Rubin is an Assistant Professor of Clinical Medicine. She attended Barnard College (1991) and Columbia University College of Physicians and Surgeons (1995), completing her Internal Medicine residency (1998) and Endocrinology fellowship training (2002) at Columbia University. Dr. Rubin also completed a Master's degree in Biostatistics at Columbia University (2006).

She received an Endocrine Fellows Foundation Award (2001), a Mentored Patient-Oriented Research Career Development Award (K23, NIH 2004-2009), a Patient-Oriented Research Track Scholarship (K30, NIH, 2004-2006) and a Young Investigator Award from the American Society of Bone and Mineral Research (2006). Dr. Rubin also received an Irving Scholarship for Young Investigators at Columbia University (2008-2011) as well as a CTSA/CTO Pilot Award (2008).

Academic Titles

  • Associate Professor of Medicine at CUMC

Committee/Societies/Council Memberships

  • Member, the Endocrine Society
    2001 - Present
  • Member, American Society for Bone and Mineral Research
    2002 - Present

Hospital Affiliations

  • NewYork-Presbyterian/Columbia

Gender

  • Female

Insurance Accepted

Aetna

  • EPO
  • HMO
  • Medicare Managed Care
  • NY Signature
  • POS
  • PPO
  • Signature Administrators
  • Student Health

Cigna

  • EPO
  • Great West
  • HMO
  • POS
  • PPO

Emblem/HIP

  • ConnectiCare
  • EPO
  • Essential Plan
  • HMO
  • Medicaid Managed Care
  • Medicare Managed Care
  • POS
  • PPO
  • Select Care (Exchange)
  • Vytra

Empire Blue Cross Blue Shield

  • Blue Priority
  • EPO
  • HMO
  • Medicare (Mediblue)
  • NYP Employee Plan
  • Pathway (Exchange)
  • POS
  • PPO

Local 1199

  • Local 1199

MagnaCare

  • MagnaCare

Multiplan

  • Multiplan

Oxford Health Plans

  • Freedom
  • Liberty
  • Medicare Managed Care

UnitedHealthcare

  • Columbia University Employee Plan
  • Compass (Exchange)
  • EPO
  • Essential Plan
  • HMO
  • Medicaid (Community Plan)
  • Medicare Managed Care
  • POS
  • PPO

*Please contact the provider’s office directly to verify that your particular insurance is accepted.

Contact & Locations

1
180 Fort Washington Avenue
New York, New York 10032
Phone:
(212) 305-2663
Fax:
(212) 342-0501
Primary

Research

Dr. Rubin's work has focused on hypoparathyroidism, as well as characterization of circulating osteogenic precursor cells, and the skeletal effects of Type 2 Diabetes Mellitus. She is currently a co-Investigator for NIH and FDA-funded studies in hypoparathyroidism and is the PI for a project investigating diabetes and bone (RC4, NIH, 2010-2012).

Grants

THERAPY OF THE SKELETAL DISEASE OF TYPE 2 DIABETES WITH DENOSUMAB (P&S Industry Clinical Trial)

Mar 20 2018 - Mar 20 2023

PROTOCOL SHP634-101, ENTITLED, ?AN OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO ASSESS THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF ONCE-DAILY AND TWICE-DAILY DOSE REGIMENS OF RECOMBINANT HUMAN PARATHYROID HORMONE (RHPTH[1-84]) (P&S Industry Clinical Trial)

Mar 16 2017 - Mar 16 2022

A PHASE 4, OPEN-LABEL, SINGLE-CENTER CLINICAL STUDY OF EXTENDED USE OF RHPTH(1-84) IN HYPOPARATHYROIDISM (P&S Industry Clinical Trial)

Sep 20 2016 - Sep 20 2021

SKELETAL DISEASE IN TYPE 2 DIABETES: A NOVEL THERAPEUTIC APPROACH FOR THE ELDERLY (Federal Gov)

Dec 15 2017 - Nov 30 2019

PRIMARY HYPERPARATHYROIDISM (Federal Gov)

Apr 1 2014 - Mar 31 2019

EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (Federal Gov)

Sep 30 2016 - Jun 30 2018

BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECT OF PTH (Federal Gov)

Dec 1 2004 - Jun 30 2017

OSTEOPOROSIS IN HIV INFECTED POSTMENOPAUSAL WOMEN (Federal Gov)

Jul 1 2010 - Jun 30 2016

TREATMENT OF HYPOPARATHYROIDISM WITH PARATHYROID HORMONE (Federal Gov)

Sep 30 2005 - Jul 31 2014

THE SKELETAL EFFECTS OF REDUCING INFLAMMATION IN TYPE 2 DIABETES MELLITUS (Federal Gov)

Sep 30 2010 - Sep 29 2013